Core Scientific’s stock valuation was adjusted down slightly from $27.65 to $26.82 per share, even as the market has shown more optimism following the Coreweave demerger. This tweak seems to reflect a bit more risk perception, with the discount rate moving from 9.04% to 9.09%. Despite this, there’s growing analyst confidence that the company could find additional value through AI and high-performance computing. We’ll see how these price targets and the overall narrative change as Core Scientific evolves.
🐂 Bullish Points
-
Macquarie recently upgraded Core Scientific to “Outperform,” with a target price set at $34, indicating a belief that the independent strategy could yield positive returns despite the recent adjustments.
-
ClearStreet raised their price target from $23 to $27, maintaining a “Buy” rating, arguing that the termination of the Coreweave deal is beneficial, helping to alleviate previous market concerns.
-
Cantor Fitzgerald’s analyst, Brett Knoblauf, kept an overweight rating and increased the price target from $18 to $26, emphasizing that whether Core Scientific pursues growth independently or reassesses its strategy, the risks and rewards are still attractive.
-
Roth Capital also recently adjusted its rating to “neutral buy” at a target of $23.50, pivoting towards a standalone model focused on monetizing its power pipeline, mainly for high-performance computing, which they believe is crucial for long-term growth.
-
Throughout their evaluations, analysts stress the importance of power, AI, managing high-performance computing demand, and executing standalone strategies as critical elements of the bullish perspective. However, they do suggest that valuation uncertainties and short-term execution risks need to be carefully navigated to justify higher targets.
🐻 Bearish Key Points
-
Roth Capital maintained a “Neutral” rating for Core Scientific, especially in comparison to its more competitive peers. They pointed out that not every operator is equally positioned to benefit from the anticipated surge in AI and data center demand due to existing colocation agreements and data center setups.
-
This cautious outlook hints that much of the expected turnaround in relation to AI and power shortages may already be priced into Core Scientific’s current valuation. Execution and capital deployment across its power initiatives are seen as vital for realizing potential additional value.
Coreweave has abandoned its planned $6.8 billion acquisition of Core Scientific after shareholders voted against it during a special meeting on October 30, 2025, leaving Core Scientific as an independent Nasdaq-listed entity under the ticker CORZ. At that same meeting, the proposed merger agreement with Coreweave was not approved, officially terminating the transaction. CoreWeave’s CEO mentioned that delays in a third-party data center contributed to missing full-year guidance, causing stocks of both companies to drop sharply following his remarks. Additionally, a lawsuit in Texas involves Core Scientific Corp. among several defendants over a transformer explosion at a Denton facility, alleging negligence and seeking over $1 million in damages for a worker’s severe burns.
The fair value estimate was slightly adjusted down, from $27.65 to $26.82 per share, suggesting a more conservative intrinsic valuation approach. The discount rate increased marginally from 9.04% to 9.09%, reflecting a slightly heightened required return and risk perception. Revenue growth remains roughly unchanged at about 62.33%, indicating stable growth expectations. The net profit margin also stayed relatively flat at approximately 27.56%, hinting at stable long-term profitability assumptions. Lastly, the forward P/E ratio dipped slightly from 33.0x to 32.1x, implying a small decrease in the valuation multiple linked to future earnings.
A narrative, in investment terms, weaves together what a company is doing with its financial projections, linking business drivers to anticipated earnings, revenue, margins, and fair value. On community pages, millions of investors employ this narrative approach to compare fair value against current stock prices, thereby influencing buy or sell decisions. As circumstances evolve, these narratives are regularly updated.
